Jul 2019

Jul 16, 2019 Quarterly Cashflow Report

Jul 01, 2019 Shareholder Update July 2019

Jun 2019

Jun 27, 2019 VivaGel® BV launched in Europe

Jun 20, 2019 Starpharma presents at Macquarie Emerging Leaders Forum

Jun 12, 2019 US patent granted for DEP Bcl2/xL inhibitor conjugates

Jun 04, 2019 Okamoto launches VivaGel® condom in Japan

Jun 03, 2019 Starpharma signs second oncology agreement with AstraZeneca

May 2019

May 29, 2019 Starpharma presents at UBS Healthcare Conference

May 24, 2019 DEP® irinotecan combination outperforms in refractory human colon cancer model

May 23, 2019 Regulatory progress for VivaGel BV in the US

May 07, 2019 Starpharma to present at US Drug Delivery Conference

May 01, 2019 Starpharma presents at Macquarie Australia Conference

Apr 2019

Apr 29, 2019 Quarterly Cashflow Report

Apr 16, 2019 Markets Live: Starpharma shares rise 13 per cent following Australian launch of VivaGel BV

Apr 16, 2019 First VivaGel BV launch globally in Australia by Aspen

Apr 11, 2019 Starpharma meets with US FDA to discuss VivaGel® BV

Apr 03, 2019 Starpharma Investor Presentation to Goldman Sachs Conference

Mar 2019

Mar 18, 2019 Shareholder Update March 2019

Mar 12, 2019 Starpharma receives $4.0M R&D tax incentive refund

Feb 2019

Feb 27, 2019 Starpharma Interim Report and Half-Year Financial Results

Jan 2019

Jan 30, 2019 Quarterly Cashflow Report

Jan 17, 2019 Shareholder Update January 2019

Jan 02, 2019 VivaGel® condom receives final regulatory approval in Japan